[go: up one dir, main page]

FR24C1054I1 - Compositions therapeutiques comprenant une antagoniste specifique pour les recepteurs a l'endotheline et un inhibiteur de la pde5 - Google Patents

Compositions therapeutiques comprenant une antagoniste specifique pour les recepteurs a l'endotheline et un inhibiteur de la pde5

Info

Publication number
FR24C1054I1
FR24C1054I1 FR24C1054C FR24C1054C FR24C1054I1 FR 24C1054 I1 FR24C1054 I1 FR 24C1054I1 FR 24C1054 C FR24C1054 C FR 24C1054C FR 24C1054 C FR24C1054 C FR 24C1054C FR 24C1054 I1 FR24C1054 I1 FR 24C1054I1
Authority
FR
France
Prior art keywords
therapeutic compositions
pde5 inhibitor
endothelin receptors
antagonist specific
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR24C1054C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38954615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR24C1054(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of FR24C1054I1 publication Critical patent/FR24C1054I1/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR24C1054C 2006-08-29 2024-12-16 Compositions therapeutiques comprenant une antagoniste specifique pour les recepteurs a l'endotheline et un inhibiteur de la pde5 Active FR24C1054I1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2006052999 2006-08-29
IB2006053857 2006-10-19
PCT/IB2007/053448 WO2008026156A2 (fr) 2006-08-29 2007-08-28 Compositions therapeutiques

Publications (1)

Publication Number Publication Date
FR24C1054I1 true FR24C1054I1 (fr) 2025-02-21

Family

ID=38954615

Family Applications (1)

Application Number Title Priority Date Filing Date
FR24C1054C Active FR24C1054I1 (fr) 2006-08-29 2024-12-16 Compositions therapeutiques comprenant une antagoniste specifique pour les recepteurs a l'endotheline et un inhibiteur de la pde5

Country Status (31)

Country Link
US (8) US8268847B2 (fr)
EP (1) EP2059246B1 (fr)
JP (1) JP5208113B2 (fr)
KR (1) KR101473022B1 (fr)
CN (1) CN101511365B (fr)
AR (1) AR062501A1 (fr)
AU (1) AU2007290099B2 (fr)
BR (1) BRPI0715698B8 (fr)
CA (1) CA2659770C (fr)
CL (1) CL2007002494A1 (fr)
CY (1) CY1114735T1 (fr)
DK (1) DK2059246T3 (fr)
ES (1) ES2438792T3 (fr)
FI (1) FIC20240045I1 (fr)
FR (1) FR24C1054I1 (fr)
HK (1) HK1133597A1 (fr)
HR (1) HRP20131233T1 (fr)
HU (1) HUS2400046I1 (fr)
IL (1) IL197235A (fr)
MA (1) MA30704B1 (fr)
MX (1) MX2009002057A (fr)
MY (1) MY154591A (fr)
NL (1) NL301308I2 (fr)
NO (1) NO342554B1 (fr)
NZ (1) NZ575702A (fr)
PL (1) PL2059246T3 (fr)
PT (1) PT2059246E (fr)
RU (1) RU2462249C2 (fr)
SI (1) SI2059246T1 (fr)
TW (1) TWI388556B (fr)
WO (1) WO2008026156A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2424805C2 (ru) 2005-09-12 2011-07-27 Актелион Фармасьютиклз Лтд Стабильные фармацевтические композиции, включающие пиримидинсульфамид
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
CA2714608A1 (fr) * 2008-02-20 2009-08-27 Actelion Pharmaceuticals Ltd Combinaison comprenant du paclitaxel destinee au traitement du cancer des ovaires
LT2315587T (lt) 2008-08-13 2018-01-10 Actelion Pharmaceuticals Ltd. Terapinės kompozicijos, turinčios macitentano
TWI462739B (zh) * 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
CN102949395A (zh) * 2011-09-22 2013-03-06 荆志成 盐酸伐地那非片在制备治疗肺动脉高压药物中的应用
CN102839165B (zh) * 2012-09-26 2014-12-10 金普诺安生物科技（苏州）有限公司 基因突变型重组蛋白酶k及其工业化生产方法
CN104411691B (zh) * 2013-06-14 2016-05-25 杭州普晒医药科技有限公司 马西替坦晶体及其制备方法、其药物组合物和用途
KR20190030805A (ko) 2017-09-14 2019-03-25 경상대학교산학협력단 폐고혈압 예방 또는 치료용 흡입제, 및 이의 투여방법
JOP20210153A1 (ar) 2018-12-21 2023-01-30 Actelion Pharmaceuticals Ltd تركيبة صيدلانية لعلاج ارتفاع ضغط الدم الشرياني الرئوي
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2801584A1 (de) * 1978-01-14 1979-07-19 Bayer Ag Halogensubstituierte pyrimidin (2)yl-thiono-thiol-phosphor(phosphon)- saeureester, verfahren zu ihrer herstellung und ihre verwendung als insektizide und akarizide
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
US5589006A (en) * 1993-11-30 1996-12-31 Canon Kabushiki Kaisha Solar battery module and passive solar system using same
IL111959A (en) 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
WO1996016963A1 (fr) 1994-11-25 1996-06-06 F. Hoffmann-La Roche Ag Sulfonamides et leur utilisation comme medicaments
TW313568B (fr) 1994-12-20 1997-08-21 Hoffmann La Roche
US5739333A (en) 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
WO1997022595A1 (fr) 1995-12-20 1997-06-26 Yamanouchi Pharmaceutical Co., Ltd. Derives arylethenesulfonamide et composition de medicaments renfermant ces derives
CH693954A5 (de) 1997-11-12 2004-05-14 Bayer Ag 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase Inhibitoren.
US6087368A (en) 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
TWI284642B (en) 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
ATE380180T1 (de) 1999-09-03 2007-12-15 Actelion Pharmaceuticals Ltd Bis-sulfonamiden
TW200400821A (en) 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
CN1407973A (zh) 1999-12-22 2003-04-02 埃科特莱茵药品有限公司 丁炔二醇衍生物
AU2001263850A1 (en) 2000-04-20 2001-11-07 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity
WO2001081338A1 (fr) 2000-04-25 2001-11-01 Actelion Pharmaceuticals Ltd Sulfonylaminopyrimidines substituees
EP1693372A1 (fr) 2000-12-18 2006-08-23 Actelion Pharmaceuticals Ltd. Nouveaux sulfamides et leur utilisation comme antagoniste du récepteur d'endotheline
DE10148883A1 (de) * 2001-10-04 2003-04-10 Merck Patent Gmbh Pyrimidinderivate
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US7094081B1 (en) * 2005-03-24 2006-08-22 Delphi Technologies, Inc. Electrical connector assembly
RU2424805C2 (ru) * 2005-09-12 2011-07-27 Актелион Фармасьютиклз Лтд Стабильные фармацевтические композиции, включающие пиримидинсульфамид
JP2009533420A (ja) * 2006-04-13 2009-09-17 アクテリオン ファーマシューティカルズ リミテッド 早期特発性肺線維症の治療

Also Published As

Publication number Publication date
BRPI0715698B8 (pt) 2021-05-25
EP2059246A2 (fr) 2009-05-20
ES2438792T3 (es) 2014-01-20
FIC20240045I1 (fi) 2024-12-16
US20210177849A1 (en) 2021-06-17
EP2059246B1 (fr) 2013-10-16
US20190083494A1 (en) 2019-03-21
US20090318459A1 (en) 2009-12-24
CN101511365A (zh) 2009-08-19
US20140148460A1 (en) 2014-05-29
RU2462249C2 (ru) 2012-09-27
PL2059246T3 (pl) 2014-03-31
AU2007290099A1 (en) 2008-03-06
TWI388556B (zh) 2013-03-11
IL197235A (en) 2014-04-30
JP5208113B2 (ja) 2013-06-12
AU2007290099B2 (en) 2013-01-31
CA2659770C (fr) 2014-11-18
AR062501A1 (es) 2008-11-12
NO20091254L (no) 2009-03-26
CL2007002494A1 (es) 2008-04-04
US20200038401A1 (en) 2020-02-06
KR20090057009A (ko) 2009-06-03
KR101473022B1 (ko) 2014-12-15
RU2009111378A (ru) 2010-10-10
BRPI0715698B1 (pt) 2020-01-21
US20130005734A1 (en) 2013-01-03
WO2008026156A3 (fr) 2008-10-16
US20200352944A1 (en) 2020-11-12
BRPI0715698A2 (pt) 2013-08-06
NO342554B1 (no) 2018-06-11
MX2009002057A (es) 2009-03-06
CA2659770A1 (fr) 2008-03-06
SI2059246T1 (sl) 2014-01-31
US20130210830A9 (en) 2013-08-15
HK1133597A1 (en) 2010-04-01
HUS2400046I1 (hu) 2025-01-28
DK2059246T3 (da) 2013-12-02
WO2008026156A2 (fr) 2008-03-06
IL197235A0 (en) 2009-12-24
MA30704B1 (fr) 2009-09-01
NL301308I2 (nl) 2024-12-30
US20180147205A1 (en) 2018-05-31
HRP20131233T1 (hr) 2014-01-31
TW200823198A (en) 2008-06-01
CN101511365B (zh) 2011-08-17
US8268847B2 (en) 2012-09-18
JP2010502588A (ja) 2010-01-28
PT2059246E (pt) 2013-12-16
CY1114735T1 (el) 2017-01-25
MY154591A (en) 2015-06-30
NZ575702A (en) 2011-11-25

Similar Documents

Publication Publication Date Title
FR24C1054I1 (fr) Compositions therapeutiques comprenant une antagoniste specifique pour les recepteurs a l'endotheline et un inhibiteur de la pde5
FR24C1038I1 (fr) Antagoniste des récepteurs de l'endothéline et de l'angiotensine ii à base de biphénylsulfonamide pour traiter la glomérulosclérose
EP2049110A4 (fr) Diazépans pontés antagonistes du récepteur de l'oréxine
FR15C0048I1 (fr) Anticorps antagonistes de il-17
MA28631B1 (fr) Antagonistes des recepteurs muscariniques de l'acetylcholine
ZA200606686B (en) Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
IL177058A0 (en) Polyheterocycilic compounds and their use as metabotropic glutamate receptor antagonists
HUS1600025I1 (hu) Egy angiotenzin receptor antagonistát és egy NEP inhibitort tartalmazó gyógyászati kombinációk
MA28363A1 (fr) Antagonistes des recepteurs muscariniques de l'acetylcholine
EP2001414A4 (fr) Prothèse d'épaule inversée
ZA200702216B (en) Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists
ZA200900303B (en) Cinnamoyl-piperazine derivatives and their use as par-i antagonists
DK1711465T3 (da) Hydroisoindolin-tachykinikreceptorantagonister
EP2062892A4 (fr) Agent améliorant l'hypertension
IL193116A0 (en) Antagonists of il-18r in diseases
EP2076285A4 (fr) Antagonistes d'anticorps du récepteur 1 de l'interleukine-13
HK1109335A1 (en) Pharmaceutical compositions based on nk2 antagonists for pediatric use
EP1970406A4 (fr) Composition de resine ionomere et tube thermoretractable l'utilisant
MA28642B1 (fr) Formes cristallines d'un pyridinyl-sulfonamide et leur utilisation comme antagonistes des recepteurs d'endotheline
ZA200902164B (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor
ITBO20060878A1 (it) Giunto per strutture d'arredamento
ES1057830Y (es) Dispensador de toallas y similares de un solo uso
UA17709S (uk) Графічний користувацький інтерфейс сайту «твой любимый харьков»
UA13934S (uk) Інтерфейс сайту «покер гетьмана»
UA12969S (uk) Комплект м'яких меблів «герцог»